Josef Smolen

46PUBLICATIONS
212CO-AUTHORS
Rheumatology and arthritisHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PharmacogenomicsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Aug 07, 2026
Ultrasound-based withdrawal of biologics in rheumatoid arthritis (RA-BioStop).

|Jan 30, 2026
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial.

Josef S Smolen, Ted R Mikuls, James Galloway

|Jul 12, 2025
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.

Gerd Burmester, Jakub Trefler, Artur Racewicz

|Jun 30, 2025
Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis.

Andreas Kerschbaumer, Marlene Steiner, Suzanne Khalili

|Jan 15, 2025
Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic Arthritis.

Sarah M Yazji, Philip S Helliwell, Andra Balanescu

|Jan 13, 2025
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.

Gerd Burmester, Piotr Adrian Klimiuk, Jakub Trefler

Pageof 8

Frequent Collaborators

11 joint publications

Daniel Aletaha

10 joint publications

Andreas Kerschbaumer

7 joint publications

Laure Gossec

6 joint publications

Maarten P T de Wit